RT Journal
A1 Daskivich T, Sadetsky N, Kaplan SH, Greenfield S, Litwin MS
T1 SEverity of comorbidity and non–prostate cancer mortality in men with early-stage prostate cancer
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2010
FD August 9
VO 170
IS 15
SP 1396
OP 1397
DO 10.1001/archinternmed.2010.251
UL http://dx.doi.org/10.1001/archinternmed.2010.251
AB 
Comorbidity is a key consideration in clinical decision making for prostate cancer. Early-stage prostate cancer often follows an indolent course, with the significant survival advantage of definitive local therapy developing at 8 years after treatment.1 Men with severe comorbidity may not live long enough to benefit from aggressive therapy and therefore may prefer to treat their disease conservatively. Unfortunately, the lack of a standardized and practical comorbidity assessment tool has limited the application of comorbidity to clinical decision making in this setting.